Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

New mechanism of action of AN-3365 linked to potent activity in Gram-negative bacterial infections

Oct. 6, 2010

Maximum tolerated dose of ARRY-380 established in patients with breast cancer

Oct. 5, 2010

Phase I data support safety of TissueGene-C in osteoarthritis

Oct. 5, 2010

Intranasal XF-73 well tolerated in phase I study

Oct. 5, 2010

Preclinical and clinical data reported on neoglycoside ACHN-490

Oct. 5, 2010

PH-797804 improves lung function in patients with COPD

Oct. 5, 2010

MedImmune reports clinical data on asthma candidates MEDI-563 and MEDI-528

Oct. 5, 2010

Phase II trial of IMA-901 shows benefit of cyclophosphamide pretreatment

Oct. 4, 2010

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Oct. 4, 2010

Phase I investigation of CombiHIVvac HIV vaccine begins

Oct. 4, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...